文献标引:汪国生，李向培.非甾体抗炎药的再认识[J/CD].中华临床医师杂志：电子版,2010,4(2):141-143.

参考文献:
[1]　Lanas A，Baron JA，Sandler RS，et al. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. Gastroenterology，2007，132（2）：490－497.[PubMed]
[2]　Graham DY，Opekun AR，Willingham FF，et al. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol，2005，3（1）：55－59.[PubMed]
[3]　Laine L，Smith R，Min K，et al. Systematic review：the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther，2006，24（5）：751－767.[PubMed]
[4]　Leite AZ，Sipahi AM，Damião AO，et al. Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID：a new mechanism. Gut，2001，48（2）：163－167.[PubMed]
[5]　Bresalier RS，Sandler RS，Quan H，et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med，2005，352（11）：1092－1102.[PubMed]
[6]　Baigent C，Patrono C. Selective COX-2 inhibitors：where do we go from here？ Lancet，2008，372（9651）：1712－1713. [PubMed]
[7]　McGettigan P，Henry D. Cardiovascular risk and inhibition of cyclooxygenase：a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA，2006，296（13）：1633－1644.[PubMed]
[8]　Grosser T，Fries S，FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition：therapeutic challenges and opportunities. J Clin Invest，2006，116（1）：4－15.[PubMed]
[9]　Solomon SD，McMurray JJ，Pfeffer MA，et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med，2005，352（11）：1071－1080.[PubMed]
[10]　American Gastroenterological Association，Wilcox CM，Allison J，et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents，including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol，2006，4（9）：1082－1089.[PubMed]
[11]　Scheiman JM，Fendrick AM. Summing the risk of NSAID therapy. Lancet，2007，369（9573）：1580－1581.[PubMed]
[12]　Zhang W，Doherty M，Leeb BF，et al. EULAR evidence based recommendations for the management of hand osteoarthritis：report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics（ESCISIT）. Ann Rheum Dis，2007，66（3）：377－388.[PubMed]
[13]　American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs：an American College of Rheumatology white paper. Arthritis Rheum，2008，59（8）：1058－1073.[PubMed]